More Depression Than Mania: Choosing Lamotrigine for Maintenance in a 38-Year-Old With Bipolar I Disorder, and the Slow Titration That Prevents a Dangerous Rash
[Student Name]
University of Phoenix
PMH/502: Neuropsychiatric Pharmacology
Week 5 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. G., a 38-year-old high school teacher with bipolar I disorder, has had one manic episode requiring hospitalization five years ago and three major depressive episodes since, the most recent ending two months ago with quetiapine, which caused weight gain of 12 kg and daytime sedation. He wants a maintenance treatment that prevents depression without these side effects. He does not drink, has normal kidney and thyroid function and takes no other medications. This paper explains the choice of lamotrigine.
The Pattern of His Illness
Mr. G.'s illness is dominated by depression, a common pattern in bipolar disorder. Maintenance treatment should prevent the kind of episode he has most often.
The Maintenance Evidence
Calabrese et al. (2003) randomly assigned recently depressed patients with bipolar I disorder to lamotrigine, lithium or placebo for 18 months. Both lamotrigine and lithium delayed the time to intervention for any mood episode compared with placebo, with median times of 200, 170 and 93 days. Lamotrigine was superior to placebo in delaying depressive episodes, and the authors concluded that lamotrigine was predominantly effective against depression and lithium against mania.
Acute Bipolar Depression
Geddes et al. (2009) conducted an individual patient data meta-analysis of five randomized trials of lamotrigine in acute bipolar depression with 1,072 participants and found a modest benefit over placebo, larger in more severely depressed patients. Lamotrigine is therefore better suited to maintenance than to rapid treatment of a severe current depression.
For a man whose illness is mostly depression, the drug that mostly prevents depression is the logical choice.
Mechanism
Lamotrigine blocks voltage-sensitive sodium channels and reduces release of glutamate, stabilizing neuronal membranes. How this prevents depressive episodes is not fully understood.
Why Not Lithium Alone
Lithium has strong evidence for preventing mania and reducing suicide, and it would remain a good option. For Mr. G., whose manic episode was five years ago and whose burden has been depression, lamotrigine's profile fits better, and it avoids lithium's monitoring of levels, kidney and thyroid function. If manic symptoms recur, lithium can be added.
The Rash Risk
Lamotrigine can cause serious rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Mockenhaupt et al. (2005) studied new users of antiepileptic drugs and found that more than 90% of these reactions occurred in the first 63 days of use, with estimated risks between 1 and 10 per 10,000 new users for lamotrigine and several other drugs. Risk is higher with rapid titration, higher starting doses and concurrent valproate, which slows lamotrigine metabolism.
The Titration
Because he takes no interacting drugs, I use the standard titration: 25 mg daily for two weeks, 50 mg daily for two weeks, 100 mg daily for one week, then 200 mg daily, the usual maintenance target. If valproate were added, doses would be halved; estrogen-containing contraceptives would require higher doses, which does not apply to him.
Rash Teaching
I teach Mr. G. to stop lamotrigine and call immediately if he develops a rash, especially with fever, mouth sores, blistering or eye involvement. Many rashes are benign, but serious ones cannot be distinguished early by the patient. If he misses more than about five half-lives, roughly five days, he must not restart at his full dose but repeat the titration.
Transition From Quetiapine
Quetiapine will be tapered slowly after lamotrigine reaches a therapeutic dose, to avoid a gap in protection and rebound insomnia.
Why Not Stay on Quetiapine
Quetiapine has evidence for bipolar depression and maintenance, and for some patients it is the right choice. For Mr. G., the 12 kg weight gain and sedation threaten his health and work, and weight gain raises the risk of diabetes and cardiovascular disease, conditions already more common in people with bipolar disorder. Switching to a weight-neutral maintenance drug addresses a real harm.
What Lamotrigine Does Not Do Well
Lamotrigine offers little protection against mania. If Mr. G. begins to show signs of mania, such as decreased need for sleep, racing thoughts or unusual spending, he and his wife should call promptly, since an antimanic agent such as lithium or an antipsychotic would be needed. I teach them these early warning signs and give them a written list.
Interactions to Remember
Valproate roughly doubles lamotrigine levels, so doses must be halved when the two are combined. Carbamazepine and some other enzyme inducers lower lamotrigine levels. Estrogen-containing contraceptives and pregnancy also lower levels, relevant for women. For Mr. G., I document these in his chart so future prescribers adjust correctly.
Suicide Risk
Bipolar disorder carries a high suicide risk, particularly during depressive episodes. I review his safety plan and note that lithium, if added, has specific evidence for reducing suicide, which may matter if depressive episodes recur.
Lifestyle and Rhythm
Regular sleep, consistent daily routines and avoiding alcohol and stimulants support mood stability. Teaching often uses the idea that mood episodes can be triggered by disruptions in routine, such as travel across time zones or late nights grading papers, and planning around them.
Adherence
Missing doses is a particular problem with lamotrigine because of the retitration rule. A weekly pill organizer and phone reminders reduce missed doses, and I explain the rule plainly so he knows to call rather than simply restart at 200 mg.
Family Involvement
His wife will join a visit to learn the rash warning signs and the early signs of mania and depression, since family members often notice changes first.
When to Consider Combination Therapy
If depressive episodes recur despite lamotrigine at an adequate dose, adding lithium or a second agent with bipolar depression evidence can be considered, weighing side effects against the benefit of preventing episodes.
Explaining the Choice
I explain to Mr. G. that lamotrigine is chosen because his illness has been mostly depression, that it is less likely to cause weight gain or sedation and that its main risk, a rare serious rash, is managed by increasing the dose slowly. He appreciates knowing why each step matters.
Documentation
The note records the pattern of episodes, the evidence behind the choice, the titration schedule and the rash teaching.
Follow-Up Timing
I will see him every two weeks during titration, when rash risk is highest, and monthly after that.
Monitoring
Mood charting, PHQ-9 scores and early warning signs of both depression and mania will be reviewed at each visit. Lamotrigine does not require routine blood levels, but a basic metabolic panel and liver tests are reasonable at baseline.
Conclusion
Mr. G.'s bipolar I disorder is dominated by depression, and an 18-month trial showed lamotrigine to be effective mainly against depressive relapse, while lithium was stronger against mania. Lamotrigine avoids the weight gain and sedation he experienced with quetiapine but requires a slow titration and clear rash teaching, because serious rash, though rare, occurs mostly in the first two months.
References
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., & DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. The Journal of Clinical Psychiatry, 64(9), 1013-1024. https://doi.org/10.4088/JCP.v64n0906
Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194(1), 4-9. https://doi.org/10.1192/bjp.bp.107.048504
Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (2005). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 64(7), 1134-1138. https://doi.org/10.1212/01.WNL.0000156354.20227.F0
How this PMH 502 Week 5 example is structured
The PMH/502 Week 5 work usually addresses mood stabilizers such as lithium and anticonvulsants. This paper matches the drug to the pattern of the patient's illness, explains its mechanism and evidence and describes the dosing rules that are part of its safety. Students search this week as PMH 502 Week 5, PMH502 Wk 5 or PMH/502 Wk 5; all three are the same assignment.
PMH/502 Week 5 questions, answered
What does PMH/502 Week 5 usually ask for?
Many sections ask students to select and monitor mood stabilizers, including lithium and anticonvulsants, for bipolar disorder.
Why is lamotrigine used in bipolar disorder?
Lamotrigine is effective mainly in preventing depressive episodes in bipolar disorder, while lithium is more effective against mania, so the choice depends on the pattern of episodes.
Why must lamotrigine be titrated slowly?
Rapid dose increases raise the risk of serious rash, including Stevens-Johnson syndrome, so doses are increased gradually over about six weeks, with adjustments when valproate or estrogen is also used.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.